EPIRUS Biopharmaceuticals Stock

EPIRUS Biopharmaceuticals ROCE 2024

EPIRUS Biopharmaceuticals ROCE

0

Ticker

EPRSQ

ISIN

US29428P1075

WKN

A117U3

In 2024, EPIRUS Biopharmaceuticals's return on capital employed (ROCE) was 0, a 0% increase from the 0 ROCE in the previous year.

EPIRUS Biopharmaceuticals Aktienanalyse

What does EPIRUS Biopharmaceuticals do?

EPIRUS Biopharmaceuticals Inc is an American biotech company specializing in the development of innovative drugs for the treatment of cancer and autoimmune diseases. It was founded in 2010 by Amit Munshi and is headquartered in Boston, Massachusetts. The company's business model is based on the use of biotechnology and advanced research and development to create specialized medications. EPIRUS aims to help patients with serious medical needs and contribute to improving healthcare worldwide. EPIRUS Biopharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling EPIRUS Biopharmaceuticals's Return on Capital Employed (ROCE)

EPIRUS Biopharmaceuticals's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing EPIRUS Biopharmaceuticals's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

EPIRUS Biopharmaceuticals's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in EPIRUS Biopharmaceuticals’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about EPIRUS Biopharmaceuticals stock

What is the ROCE (Return on Capital Employed) of EPIRUS Biopharmaceuticals this year?

The ROCE of EPIRUS Biopharmaceuticals is 0 undefined this year.

How has the ROCE (Return on Capital Employed) of EPIRUS Biopharmaceuticals developed compared to the previous year?

The ROCE of EPIRUS Biopharmaceuticals has increased by 0% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of EPIRUS Biopharmaceuticals?

A high Return on Capital Employed (ROCE) indicates that EPIRUS Biopharmaceuticals has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of EPIRUS Biopharmaceuticals?

A low ROCE (Return on Capital Employed) can indicate that EPIRUS Biopharmaceuticals has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from EPIRUS Biopharmaceuticals impact the company?

An increase in the ROCE of EPIRUS Biopharmaceuticals can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of EPIRUS Biopharmaceuticals affect the company?

A decrease in ROCE of EPIRUS Biopharmaceuticals can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of EPIRUS Biopharmaceuticals?

Some factors that can affect EPIRUS Biopharmaceuticals's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of EPIRUS Biopharmaceuticals so important for investors?

The ROCE of EPIRUS Biopharmaceuticals is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can EPIRUS Biopharmaceuticals take to improve the ROCE?

To improve the ROCE, EPIRUS Biopharmaceuticals can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does EPIRUS Biopharmaceuticals pay?

Over the past 12 months, EPIRUS Biopharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, EPIRUS Biopharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of EPIRUS Biopharmaceuticals?

The current dividend yield of EPIRUS Biopharmaceuticals is .

When does EPIRUS Biopharmaceuticals pay dividends?

EPIRUS Biopharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of EPIRUS Biopharmaceuticals?

EPIRUS Biopharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of EPIRUS Biopharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is EPIRUS Biopharmaceuticals located?

EPIRUS Biopharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von EPIRUS Biopharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of EPIRUS Biopharmaceuticals from 11/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/1/2024.

When did EPIRUS Biopharmaceuticals pay the last dividend?

The last dividend was paid out on 11/1/2024.

What was the dividend of EPIRUS Biopharmaceuticals in the year 2023?

In the year 2023, EPIRUS Biopharmaceuticals distributed 0 USD as dividends.

In which currency does EPIRUS Biopharmaceuticals pay out the dividend?

The dividends of EPIRUS Biopharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von EPIRUS Biopharmaceuticals

Our stock analysis for EPIRUS Biopharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of EPIRUS Biopharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.